Zachmann M, Eiholzer U, Muritano M, Werder E A, Manella B
Acta Endocrinol Suppl (Copenh). 1986;279:218-26. doi: 10.1530/acta.0.112s218.
22 Boys with pubertal gynaecomastia (age 15.9 +/- 1.9 years) were treated with testolactone (450 mg daily by mouth) for 2 to 6 months without side-effects. The mean breast gland diameter regressed from 4.4 to 3.3, 3.2 cm, and 1.7 cm at 2, 4, and 6 months, while pubic hair and testicular volume progressed normally. Plasma androstenedione increased from 5.4 to 73.1 nmol/l. Testosterone, DHEA, and oestrone increased less, and oestradiol remained unchanged. Androgen/oestrogen ratios increased (most marked change: androstenedione/oestrone from 15 to 140). LH (basal and maximum after LHRH) did not change, but FSH increased somewhat (basal 133 to 173, maximum 225 to 269 micrograms/l). Prolactin remained unchanged. It is concluded that testolactone, an inhibitor of steroid aromatization, is an effective and safe medical treatment for pubertal gynaecomastia.
22名青春期男性乳房肥大症男孩（年龄15.9±1.9岁）接受了睾内酯治疗（每日口服450毫克），持续2至6个月，未出现副作用。在2个月、4个月和6个月时，平均乳腺直径分别从4.4厘米降至3.3厘米、3.2厘米和1.7厘米，而阴毛和睾丸体积正常发育。血浆雄烯二酮从5.4纳摩尔/升增至73.1纳摩尔/升。睾酮、脱氢表雄酮和雌酮增加较少，雌二醇保持不变。雄激素/雌激素比值升高（最显著变化：雄烯二酮/雌酮从15增至140）。促黄体生成素（基础值及促性腺激素释放激素刺激后的最大值）未改变，但促卵泡生成素略有增加（基础值从133微克/升增至173微克/升，最大值从225微克/升增至269微克/升）。催乳素保持不变。结论是，甾体芳香化酶抑制剂睾内酯是治疗青春期男性乳房肥大症的一种有效且安全的药物。
